IMMUNIC, INC. 8-K

What Happened Immunic, Inc. (IMUX) announced that Nasdaq notified the company on March 27, 2026 that it has regained compliance with Nasdaq Listing Rule 5550(a)(2) (the minimum bid price requirement). Nasdaq determined Immunic maintained a minimum closing bid of at least $1.00 per share for 20 consecutive business days from February 27, 2026 through March 26, 2026. The company issued a press release on April 1, 2026 confirming receipt of the Nasdaq letter and that the matter is closed.

Key Details

• Maintained a minimum closing bid of at least $1.00 per share for 20 consecutive business days (Feb 27, 2026–Mar 26, 2026).
• Nasdaq sent written notification (the “Nasdaq Letter”) on March 27, 2026 confirming compliance and closing the matter.
• Immunic issued a press release on April 1, 2026; the release is attached as Exhibit 99.1 to the Form 8‑K.
• Rule referenced: Nasdaq Listing Rule 5550(a)(2) (Minimum Bid Price Requirement).

Why It Matters Regaining compliance removes the immediate risk of delisting tied to the stock’s bid price and preserves Immunic’s continued listing on Nasdaq, which supports liquidity and market access for shareholders. The filing is limited to this compliance update and a related press release; it does not report earnings, executive changes, or other material corporate events.